Table 4. Quality and risk of bias assessment.
| Source | Randomisation | Control | Blinding | Design of experiments | Cochrane risk of bias assessment tool | Funding | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | ||||||
| Reimer (2008) | yes | Other treatment | NO | Crossover | L | U | H | H | L | L | The efficacy of the injection was not assessed | Industrial |
| Koek (2009) | yes | Other treatment | NO | Parallel-group | L | L | H | H | L | L | The severity of psoriasis was not defined as an inclusion criterion | Public |
| Oude Elberink (2009) | partial | Other treatment | NO | Parallel-group | H | H | H | H | H | L | Some participants were recruited through advertising campaigns | Industrial |
| Ishii (2011) | NO | NO | NO | No control | H | H | H | H | H | L | Industrial | |
| Martin (2013) | yes | Other treatment | NO | Parallel-group | U | U | H | H | L | U | Industrial | |
| Bilton (2014) | yes | Other treatment | NO | Parallel-group | U | U | H | H | L | U | Unclear | |
| Quittner (2015) | yes | Placebo | participants + care providers | Parallel-group | U | U | L | L | L | L | Industrial | |
| Garg (2016) | yes | Other treatment | NO | Crossover | L | U | H | H | L | L | Industrial | |
| Kabul (2016) | yes | Other treatment | NO | Parallel-group | L | L | H | H | L | L | Industrial | |
| Salisbury (2018) | yes (clusters) | Other treatment | analyst | Parallel-group | L | L | H | L | H | L | Particular profile of eligible practices: 2+ physicians, 4,500+ registered patients | Public |
| Ishii (2019) | yes | Other treatment | NO | Parallel-group | U | U | H | H | L | L | Industrial | |
1 = Random sequence generation, 2 = Allocation sequence concealment, 3 = Blinding of participants & staff, 4 = Blinding of outcome assessment, 5 = Incomplete outcome data, 6 = Selective reporting, 7 = Other sources of bias. L = low, H = high, U = unclear.